Curated research, regulatory updates, and industry moves — filtered through a longevity lens. Updated weekly.
Week of September 15, 2026
A new systematic review catalogs every intervention shown to decrease next-generation epigenetic aging clocks in humans. The paper consolidates data across DunedinPACE, GrimAge, and PhenoAge clocks — making it the most comprehensive reference for evidence-based age reversal.
After years of regulatory uncertainty following the FDA's 2022 position on NMN as a drug under investigation, the supplement industry continues to adapt. Multiple companies now offer NMN under different regulatory frameworks. The science remains strong — the regulatory path continues to evolve.
Emerging clinical data continues to refine optimal rapamycin dosing for longevity in otherwise healthy adults. The key question: can low-dose, intermittent rapamycin capture the mTOR inhibition benefits without immunosuppression? Early results are encouraging.
The cost of epigenetic age testing continues to drop. What was a $500+ test three years ago is now available for under $200 from multiple providers. As accessibility increases, so does the quality of population-level aging data.
The studies shaping the future of longevity science.
The senolytic field continues to mature with multiple clinical trials evaluating fisetin, dasatinib+quercetin, and novel small molecules. Unity Biotechnology and other companies are publishing results from targeted senolytic therapies in specific age-related conditions.
Research into mitochondrial transfer — moving healthy mitochondria from young cells to aged cells — continues to show promise in preclinical models. If translatable, this could address mitochondrial dysfunction at its source rather than through supplementation.
Partial cellular reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc) continues to advance. The challenge remains achieving rejuvenation without dedifferentiation. Altos Labs, NewLimit, and others are publishing new approaches to this "Goldilocks zone" of reprogramming.